Chinese Medical Sciences Journal ›› 2011, Vol. 26 ›› Issue (2): 77-84.doi: 10.1016/S1001-9294(11)60024-2
• Original Article • Previous Articles Next Articles
Lu Lu, Lei Li, Xiang Lv, Xue-song Wu, De-pei Liu*, and Chih-chuan Liang
Received:
2011-06-24
Revised:
2011-06-24
Online:
2011-06-24
Published:
2011-06-24
Lu Lu, Lei Li, Xiang Lv, Xue-song Wu, De-pei Liu*, and Chih-chuan Liang. Inhibition of SIRT1 Increases EZH2 Protein Level and Enhances the Repression of EZH2 on Target Gene Expression[J].Chinese Medical Sciences Journal, 2011, 26(2): 77-84.
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
1. | KennisonJA. The Polycomb and trithorax group proteins of Drosophila: trans-regulatorsof homeotic gene function . Annu RevGenet 1995; 29:289-303. |
2. | BrackenAP, Dietrich N, Pasini D, et al. Genome-wide mapping of Polycomb target genesunravels their roles in cell fate transitions . Genes Dev 2006; 20:1123-36. |
3. | SchwartzYB, Kahn TG, Nix DA, et al. Genome-wide analysis of Polycomb targets inDrosophila melanogaster . Nat Genet2006; 38:700-5. |
4. | Boyer LA,Plath K, Zeitlinger J, et al. Polycomb complexes repress developmentalregulators in murine embryonic stem cells .Nature 2006; 441:349-53. |
5. | Czermin B,Melfi R, McCabe D, et al. Drosophila enhancer of Zeste/ESC complexes have ahistone H3 methyltransferase activity that marks chromosomal Polycomb sites . Cell 2002; 111:185-96. |
6. | M黮ler J,Hart CM, Francis NJ, et al. Histone methyltransferase activity of a DrosophilaPolycomb group re- pressor complex .Cell 2002; 111:197-208. |
7. | KuzmichevA, Nishioka K, Erdjument-Bromage H, et al. Histone methyltransferase activityassociated with a human multiprotein complex containing the Enhancer of Zesteprotein . Genes Dev 2002; 16:2893-905. |
8. | Cao R , Wang L, Wang H, et al. Role of histone H3 lysine 27methylation in Polycomb-group silencing .Science 2002; 298:1039-43. |
9. | Pasini D,Bracken AP, Jensen MR, et al. Suz12 is essential for mouse development and forEZH2 histone methyltransferase activity .EMBO J 2004; 23:4061-71. |
10 | Simon JA,Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics . Mutat Res 2008; 647:21-9. |
11 | Mills AA.Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins . Nat Rev Cancer 2010; 10:669-82. |
12 | BrackenAP, Pasini D, Capra M, et al. EZH2 isdownstream of the pRB-E 2F pathway, essential for proliferation and amplified in cancer . EMBO J 2003; 22:5323-35. |
13 | Bohrer LR,Chen S, Hallstrom TC, et al. Androgens suppress EZH2 expression viaretinoblastoma (RB) and p130-dependent pathways: a potential mechanism ofandrogen-refractory progression of prostate cancer . Endocrinology 2010; 151:5136-45. |
14 | VaramballyS,Cao Q , Mani RS,et al. Genomic loss of microRNA-101 leads to overexpression of histone methy- ltransferaseEZH 2 incancer . Science 2008; 322:1695-9. |
15 | CiarapicaR, Russo G, Verginelli F, et al. Deregulated expression of miR -26aand Ezh 2 inrhabdomyosarcoma .Cell Cycle 2009; 8:172-5. |
16 | Juan AH,Kumar RM, Marx JG, et al. Mir-214-dependent regulation of the polycomb proteinEzh 2 inskeletal muscle andembryonic stem cells . Mol Cell 2009;36:61-74. |
17 | KislioukT, Yosefi S, Meiri N. MiR-138 inhibits EZH2 methyltransferase expression andmethylation of histone H3 at lysine 27, and affects thermotolerance acquisition . Eur J Neurosci 2011; 33:224-35. |
18 | Tan J,Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressivecomplex 2-mediated gene repression selectively induces apoptosis in cancercells . Genes Dev 2007; 21:1050-63. |
19 | Dimri M,Bommi PV, Sahasrabuddhem AA, et al. Dietary omega-3 polyunsaturated fatty acidssuppress expression of EZH 2 in breast cancer cells . Carcinogenesis2010; 31:489-95. |
20 | Fiskus W,Pranpat M, Balasis M, et al. Histone deacetylase inhibitors deplete enhancer ofzeste 2 and associated polycomb repressive complex 2 proteins in human acuteleukemia cells . Mol Cancer Ther 2006;5:3096-104. |
21 | Haigis MC,Sinclair DA. Mammalian sirtuins: biological insights and disease relevance . Annu Rev Pathol 2010; 5:253-95. |
22 | KuzmichevA, Margueron R, Vaquero A, et al. Composition and histone substrates ofpolycomb repressive group complexes change during cellular differentiation . Proc Natl Acad Sci U S A 2005;102:1859-64. |
23 | Li L, LuL, L? X, et al. Epigenetic repression of SATB1 by Polycomb group protein EZH 2 inepithelial cells . Chin Med Sci J 2010; 25:199-205. |
24 | Vaziri H, Dessain SK,Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase . Cell 2001; 107:149-59. |
25 | Brunet A,Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXOtranscription factors by the SIRT1 deacetylase . Science 2004; 303:2011-5. |
26 | Chen WY, Wang DH, Yen RC, et al. Tumor suppressor HIC1 directlyregulates SIRT1 to modulate p53-dependent DNA-damage responses . Cell 2005; 123:437-48. |
27 | Wang C,Chen L, Hou X, et al. Interactions between E 2F 1 and SirT1 regulate apoptotic response to DNAdamage . Nat Cell Biol 2006;8:1025-31. |
28 | Vaquero A,Scher M, Erdjument-Bromage H, et al. SIRT1 regulates the histonemethyl-transferase SUV39H1 during heterochromatin formation . Nature 2007; 450:440-4. |
29 | Vaquero A,Scher M, Lee D, et al. Human SirT1 interacts with histone H1 and promotesformation of facultative heterochromatin .Mol Cell 2004; 16:93-105. |
30 | Kurdistani SK, Tavazoie S, Grunstein M. Mapping global histoneacetylation patterns to gene expression .Cell 2004; 117:721-33. |
31 | Pruitt K,Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer geneswithout loss of promoter DNA hypermethylation . PLoS Genet 2006; 2:e40. |
32 | Wang RH,Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, andtumorigenesis in SIRT1 mutant mice .Cancer Cell 2008; 14:312-23. |
33 | Deng CX.SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci 2009;5:147-52. |
[1] | Lei Li, Lu Lu, Xiang Lü, Xue-song Wu, De-pei Liu and Chih-chuan Liang. Epigenetic repression of SATB1 by Polycomb group protein EZH2 in epithelial cells [J]. Chinese Medical Sciences Journal, 2010, 25(4): 199-205. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
|
Supervised by National Health Commission of the People's Republic of China
9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China
Tel: 86-10-65105897 Fax:86-10-65133074
E-mail: cmsj@cams.cn www.cmsj.cams.cn
Copyright © 2018 Chinese Academy of Medical Sciences
All right reserved.
京公安备110402430088 京ICP备06002729号-1